JP2020506221A5 - - Google Patents

Download PDF

Info

Publication number
JP2020506221A5
JP2020506221A5 JP2019556568A JP2019556568A JP2020506221A5 JP 2020506221 A5 JP2020506221 A5 JP 2020506221A5 JP 2019556568 A JP2019556568 A JP 2019556568A JP 2019556568 A JP2019556568 A JP 2019556568A JP 2020506221 A5 JP2020506221 A5 JP 2020506221A5
Authority
JP
Japan
Prior art keywords
antibody
fab fragment
polypeptide
seq
polyclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556568A
Other languages
English (en)
Japanese (ja)
Other versions
JP7661008B2 (ja
JP2020506221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012255 external-priority patent/WO2018129092A1/en
Publication of JP2020506221A publication Critical patent/JP2020506221A/ja
Publication of JP2020506221A5 publication Critical patent/JP2020506221A5/ja
Priority to JP2023001681A priority Critical patent/JP2023033394A/ja
Priority to JP2025016938A priority patent/JP2025067928A/ja
Application granted granted Critical
Publication of JP7661008B2 publication Critical patent/JP7661008B2/ja
Priority to JP2025104762A priority patent/JP2025126236A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556568A 2017-01-04 2018-01-03 バイオフィルム関連障害の処置のための抗体断片 Active JP7661008B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023001681A JP2023033394A (ja) 2017-01-04 2023-01-10 バイオフィルム関連障害の処置のための抗体断片
JP2025016938A JP2025067928A (ja) 2017-01-04 2025-02-04 バイオフィルム関連障害の処置のための抗体断片
JP2025104762A JP2025126236A (ja) 2017-01-04 2025-06-20 バイオフィルム関連障害の処置のための抗体断片

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762442307P 2017-01-04 2017-01-04
US62/442,307 2017-01-04
US201762453921P 2017-02-02 2017-02-02
US62/453,921 2017-02-02
PCT/US2018/012255 WO2018129092A1 (en) 2017-01-04 2018-01-03 Antibody fragments for the treatment of biofilm-related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023001681A Division JP2023033394A (ja) 2017-01-04 2023-01-10 バイオフィルム関連障害の処置のための抗体断片

Publications (3)

Publication Number Publication Date
JP2020506221A JP2020506221A (ja) 2020-02-27
JP2020506221A5 true JP2020506221A5 (https=) 2021-02-12
JP7661008B2 JP7661008B2 (ja) 2025-04-14

Family

ID=61025090

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019556568A Active JP7661008B2 (ja) 2017-01-04 2018-01-03 バイオフィルム関連障害の処置のための抗体断片
JP2023001681A Pending JP2023033394A (ja) 2017-01-04 2023-01-10 バイオフィルム関連障害の処置のための抗体断片
JP2025016938A Pending JP2025067928A (ja) 2017-01-04 2025-02-04 バイオフィルム関連障害の処置のための抗体断片
JP2025104762A Pending JP2025126236A (ja) 2017-01-04 2025-06-20 バイオフィルム関連障害の処置のための抗体断片

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023001681A Pending JP2023033394A (ja) 2017-01-04 2023-01-10 バイオフィルム関連障害の処置のための抗体断片
JP2025016938A Pending JP2025067928A (ja) 2017-01-04 2025-02-04 バイオフィルム関連障害の処置のための抗体断片
JP2025104762A Pending JP2025126236A (ja) 2017-01-04 2025-06-20 バイオフィルム関連障害の処置のための抗体断片

Country Status (6)

Country Link
US (1) US12098188B2 (https=)
EP (1) EP3565834B1 (https=)
JP (4) JP7661008B2 (https=)
AU (1) AU2018206560B9 (https=)
CA (1) CA3049114A1 (https=)
WO (1) WO2018129092A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
CN112771074A (zh) 2018-10-05 2021-05-07 国家儿童医院研究所 用于酶促破坏细菌生物膜的组合物和方法
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3760984A (en) 1971-09-29 1973-09-25 Alza Corp Osmotically powered agent dispensing device with filling means
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3923426A (en) 1974-08-15 1975-12-02 Alza Corp Electroosmotic pump and fluid dispenser including same
US4036228A (en) 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4016880A (en) 1976-03-04 1977-04-12 Alza Corporation Osmotically driven active agent dispenser
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4203442A (en) 1977-08-29 1980-05-20 Alza Corporation Device for delivering drug to a fluid environment
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4210139A (en) 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
DE3424893A1 (de) 1984-07-06 1986-02-06 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches silberhalogenidaufzeichnungsmaterial
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE229046T1 (de) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
ES2196002T3 (es) 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
RU2212899C2 (ru) 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US20050131222A1 (en) 1995-04-21 2005-06-16 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof
US6355450B1 (en) 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
NZ331186A (en) 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
ES2230848T3 (es) 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
JP2003527439A (ja) 2000-03-17 2003-09-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ１８抗体と抗ｃｃｒ２抗体の混合物を用いる狭窄および再狭窄を抑制する方法
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
AU2002307448A1 (en) 2001-04-20 2002-11-05 President And Fellows Of Harvard College Methods and compositions for the modulation of biofilm formation
WO2004001058A2 (en) 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AU2002328203C1 (en) 2001-08-24 2009-01-08 Migenix Inc. Antimicrobial and anti-inflammatory peptides
US20030099602A1 (en) 2001-10-25 2003-05-29 Levin Gilbert V. D-tagatose as an anti-biofilm agent
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US7297340B2 (en) 2003-01-07 2007-11-20 University Of Iowa Research Foundation Vaccine and method for preventing biofilm formation
CA2796381A1 (en) 2003-03-06 2004-09-16 Children's Hospital, Inc. Genes of an otitis media isolate of nontypeable haemophilus influenzae
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
US20090029929A1 (en) 2004-03-26 2009-01-29 Locomogene, Inc. Decoy Nucleic Acid to Synoviolin Gene Promoter
GB0410866D0 (en) * 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
EP1799255A4 (en) 2004-06-25 2008-10-01 Medimmune Vaccines Inc RECOMBINANT HUMANESE CYTOMEGALOVIRUS AND HETEROLOGIST ANTIGENS CONTAINING VACCINES
US20060030539A1 (en) 2004-08-06 2006-02-09 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
US20060228384A1 (en) 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
CA2871088A1 (en) 2005-06-16 2006-12-28 Lauren O. Bakaletz Genes of an otitis media isolate of nontypeable haemophilus influenzae
EP1943344A2 (en) 2005-10-04 2008-07-16 The Ludwig Institute for Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
US20090264342A1 (en) 2006-02-13 2009-10-22 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
CA2660668C (en) 2006-08-21 2016-06-28 The University Of British Columbia Small cationic antimicrobial peptides
EP1980269A1 (en) 2007-04-13 2008-10-15 Katholieke Universiteit Leuven Prevention of staphylococcus biofilm formation
WO2009006699A1 (en) 2007-07-12 2009-01-15 Oral Health Australia Pty Ltd Biofilm treatment
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
CN103097399A (zh) * 2010-03-29 2013-05-08 南加利福尼亚大学 用于去除生物膜的组合物及方法
EP2613797B1 (en) 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
US9746475B2 (en) 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
US20130183323A1 (en) 2011-12-19 2013-07-18 Hua Wang Targeted antibiotic and antimicrobial treatments for personalized administration
AU2013266069B2 (en) 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
ES2746971T3 (es) * 2013-06-13 2020-03-09 Res Inst Nationwide Childrens Hospital Composiciones y procedimientos para el tratamiento de infecciones por burkholderia
US20160194384A1 (en) * 2014-06-12 2016-07-07 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US20160289287A1 (en) 2013-08-27 2016-10-06 The University Of British Columbia Small cationic anti-biofilm and idr peptides
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US20150086561A1 (en) 2013-09-26 2015-03-26 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US20150197558A1 (en) 2013-09-26 2015-07-16 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US20150299298A1 (en) 2013-09-26 2015-10-22 Trellis Bioscience, Llc Binding moieties for biofilm remediation
BR112016013514B1 (pt) * 2013-12-13 2022-04-19 Stora Enso Oyj (Fi) Papelão de múltiplas camadas
EP3049113B1 (en) 2014-01-13 2023-12-27 Trellis Bioscience, LLC Binding moieties for biofilm remediation
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
WO2016154491A1 (en) 2015-03-25 2016-09-29 Trellis Bioscience, Llc Binding moieties for biofilm remediation
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
CN109069871A (zh) 2015-12-04 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的新抗体
US20170182205A1 (en) 2015-12-28 2017-06-29 ProclaRx LLC Medical devices with biofilm disruptors
WO2017192594A1 (en) 2016-05-02 2017-11-09 Trellis Bioscience, Llc Binding moieties for biofilm remediation
AU2017319702B2 (en) 2016-09-02 2024-11-14 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Similar Documents

Publication Publication Date Title
JP2020506221A5 (https=)
Gil et al. Biofilm matrix exoproteins induce a protective immune response against Staphylococcus aureus biofilm infection
US11911472B2 (en) Monoclonal antibody and vaccine targeting filamentous bacteriophage
Johnson The pathogenicity of enterococci
Novotny et al. Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo
JP4424984B2 (ja) コアグラーゼ陰性ブドウ球菌および黄色ブドウ球菌由来の表面蛋白質を認識する、交差反応性モノクローナルおよびポリクローナル抗体
JP2020513838A5 (https=)
Archana et al. Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model
Van Dam et al. Capnocytophaga canimorsus infections in The Netherlands: a nationwide survey
EP2746394A1 (en) Antibody and antibody-containing composition
US12152068B2 (en) Binding moieties for biofilm remediation
WO2015048484A2 (en) Binding moieties for biofilm remediation
CN119241697B (zh) 抗金黄色葡萄球菌铁离子调节表面决定簇b蛋白的单克隆抗体及应用
RU2560415C2 (ru) Антитела или их фрагменты, направленные против эпитопа стафилококка золотистого (staphylococcus aureus)
Zhen et al. Characterization of specific egg yolk immunoglobulin (IgY) against mastitis‐causing Staphylococcus aureus
WO2016154491A1 (en) Binding moieties for biofilm remediation
Shiro et al. The pathogenic role of Staphylococcus epidermidis capsular polysaccharide/adhesin in a low-inoculum rabbit model of prosthetic valve endocarditis
RU2707738C1 (ru) Антибактериальная композиция и способ лечения стафилококковых инфекций антибактериальной композицией
Gong et al. Immune responses and protective efficacy of a trivalent combination DNA vaccine based on oprL, oprF and flgE genes of Pseudomonas aeruginosa
JP6934904B2 (ja) バイオフィルム除去のための結合モイエティ
Durand Nasal infections
Hofseth et al. Infectious tenosynovitis with bloodstream infection caused by Erysipelothrix rhusiopathiae, a case report on an occupational pathogen
Selvabai et al. Characterization of methicillin resistant Staphylococcus aureus based on its virulence factors and antimicrobial susceptibility profile
Ison et al. Characterisation of monoclonal antibodies for detection of Mobiluncus spp. in genital specimens
TWI430808B (zh) 外膜蛋白ａ於治療／預防／診斷中樞神經系統與周邊血液細菌感染之用途